Haemonetics (HAE) Tops Q2 EPS by 16c; offers guidance
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $72.53 -2.21%
EPS Growth %: -0.9%
Financial Fact:
Cost of goods sold: 116.01M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -0.9%
Financial Fact:
Cost of goods sold: 116.01M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q2 EPS of $1.27, $0.16 better than the analyst estimate of $1.11. Revenue for the quarter came in at $327 million versus the consensus estimate of $311.46 million.
GUIDANCE:
Haemonetics sees FY2026 EPS of $4.80-$5.00, versus the consensus of $4.83.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Magnachip launches two 600V SJ MOSFETs for AI servers and EV charging
- Comfort Systems USA names new COO and Chief Strategy Officer
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
